SCYNEXIS Inc. announced that a novel series of antifungal compounds from its proprietary triterpenoid antifungal platform will be part of a new federally funded research initiative. The five-year federal grant, totaling approximately $7 million annually, was awarded to a consortium led by researchers from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the Johns Hopkins Bloomberg School of Public Health, with SCYNEXIS and other academic and commercial collaborators participating. The funding, provided by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID), will support the Center of Excellence in Translational Research (CETR) and accelerate the development of new therapeutics for resistant fungal infections, including SCYNEXIS's next-generation fungerp candidates.